Bristol Myers Squibb announced that its Board of Directors has unanimously elected Christopher Boerner, Ph.D., to serve as Chair of the Board, effective April 1, 2024. He succeeds Giovanni Caforio, M.D., who will step down as Chair of the Board…
Bristol Myers Squibb today announced that Opdivo®(nivolumab) was approved by the U.S. Food and Drug Administration (FDA) for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected stage IIB or IIC melanoma, expanding upon…
With cancer patients top of mind, teams of Bristol Myers Squibb employees will celebrate a decade of Coast 2 Coast 4 Cancer (C2C4C) this year and cycle nearly 3,000 miles from Oregon to New Jersey with the goal of raising…